

---

## Published Literature from scheme staff

---

### Trace Elements scheme

1. Duncan A, **Harrington C**, Catchpole A, Taylor, [Is the Measurement of Copper and Iron in Liver Biopsies Reliable? Results from a Pilot External Quality Assurance Scheme](#). *J. of Trace Elem. Med. and Biol.* 2019, 52, 288-292
2. Sarah-Jane Bainbridge and **Chris F. Harrington**. External Quality Assessment (EQA) for Trace Element Measurements in Clinical Laboratories. *Clinical Laboratory International*. Feb/March 2015, pp19-21.
3. Meredith L Praamsma, Josiane Arnaud, David Bisson, Stuart Kerr, **Chris F. Harrington**, Patrick J Parsons. [An assessment of clinical laboratory performance for the determination of manganese in blood and urine](#). *Clinical Chemistry and Laboratory Medicine*, 54(12):1921-1928, (2016).
4. **Chris F. Harrington** and Andrew Taylor. Measurement of Cobalt and Chromium in Whole Blood External Quality Assurance Specimens in the UK, April 2011 to March 2012. *BMJ: British Medical Journal* 344 (7861), 30-30, (2012). <http://www.bmj.com/content/344/bmj.e1410/rr/586587>
5. T. Catterick, B. Fairman, and **C. F. Harrington**. [A structured approach to achieving high accuracy measurements with isotope dilution inductively coupled plasma mass spectrometry](#). *Journal of Analytical Atomic Spectrometry*, Vol. 13, p1009 - 1013 (1998).
6. P. Sutton, **C. F. Harrington**, B. Fairman, H. Evans, L. Ebdon and T. Catterick. [The small-scale synthesis and NMR characterisation of isotopically enriched organotin compounds](#). *Applied Organometallic Chemistry*. Vol. 14, 691 – 700, (2000).
7. C. S. J. Wolff-Briche, **C. Harrington**, T. Catterick and B. Fairman. [Orthodox uncertainty budgeting for high accuracy measurements by isotope dilution inductively coupled plasma mass spectrometry](#). *Analytica Chimica Acta* 437, 1-10, (2001).
8. P. Evans, B. Fairman, C. Wolff-Briche, S. Merson and **C. F. Harrington**. [The performance of commercial mono-elemental solutions for high accuracy mass spectrometry](#), *In, Plasma Source Mass Spectrometry: The New Millennium*. Edited by G. Holland and S. D. Tanner. RSC Special Publication. ISBN 0-85404-895-2. P245 – 256, 2001.
9. [Guidelines for achieving high accuracy in inorganic and organic analysis by isotope dilution mass spectrometry](#). Editors M. Sargent, R. Harte and **C. Harrington**. *RSC Special Publication* (2002), ISBN 0-854-044183.
10. **Chris F. Harrington**, Daniel S. Vidler, Michael J. Watts and John Hall. [The potential for using isotopically labelled metalloproteins for species-specific isotope dilution mass spectrometry](#). *Analytical Chemistry*, Vol. 77, p4034-4041, (2006).

11. Pritesh Patel, Phil Jones, Richard Handy, **Chris Harrington**, Peter Marshall and E. Hywel Evans. [Isotopic labelling of peptides and isotope ratio analysis using LC-ICP-MS: a preliminary study](#). Short communication *Analytical and Bioanalytical Chemistry. Special Issue*, 390(1):61-65, (2007). DOI 10.1007/s00216-007-1432-7.
12. D. Koller, P. Bramhall, J. Devoy, H. Goenaga-Infante, **C.F. Harrington**, S. Nunez, J. Morton, L. Leese, B. Sampson and J.J. Powell. Analysis of titanium in human whole blood by methods based on inductively coupled plasma: an inter-laboratory comparison to determine best practice. *Analyst*, 2018, 143, 5520–5529.
13. [Report to IMEP on the methylmercury mass fraction of tuna fish as part of the IMEP-20 trace elements in tuna fish study](#) (2003). Prepared by D.S. Vidler and **C.F. Harrington**.
14. J. Turner and **C. F. Harrington**. Different approaches to overcoming mass interference problems in ICP-MS. VAM task 4.2.1.4.b. Investigating the influence of mass spectral interferences on isotope dilution measurements. VAM document number LGC/VAM/1999/039, (1999).
15. **C. F. Harrington**. The role of isotopic internal standards in speciation analysis. VAM task 4.2.1.5b application of mass spectrometry with on-line separations. VAM document number LGC/VAM/1999/040, (1999).
16. T. Catterick, B. Fairman, **C.F. Harrington**. A comparison of magnetic sector and quadrupole instruments for isotope dilution mass spectrometry (IDMS) measurements (1998). VAM task 4.2.1.1 calibration for high accuracy isotope dilution mass spectrometry (IDMS) measurements. VAM document number LGC/VAM/1998/094, (1998).
17. [T. Catterick, B. Fairman, C.F. Harrington. A structured approach to achieving high accuracy measurements with inductively coupled plasma isotope dilution mass spectrometry](#) (1998). VAM project 4.2.1 mass spectrometry for inorganic analysis. VAM document number LGC/VAM/1998/018, (1998).

### Guildford Peptide Hormones

1. Malipatil N, Fachim HA, Siddals K, Geary B, **Wark G**, Porter N, Anderson S, Donn R, Harvie M, Whetton AD, Gibson MJ, Heald A. [Data Independent Acquisition Mass Spectrometry Can Identify Circulating Proteins That Predict Future Weight Loss with a Diet and Exercise Programme](#). *J Clin Med*. 2019 Jan 25;8(2). pii: E141. doi: 10.3390/jcm8020141
2. *N.Thanawala, S.Cheney, G. Wark, M. Thevis, A. Thomas, W. Madira, V. Tziaferi, J. Greening.* [Fictitious administration of analogue insulin to a 2-year-old child](#). *British Journal of Diabetes* 2016; 16(2): 82-84.
3. Parfitt C, Church D, Armston A, Couchman L, Evans C, **Wark G**, McDonald TJ. [Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues](#). *Clin Biochem*. 2015; 48(18):1354-1357.
4. Jassam N, Amin N, Holland P, Semple RK, Halsall DJ, **Wark G**, Barth JH. [Analytical and clinical challenges in a patient with concurrent type 1 diabetes, subcutaneous insulin resistance and insulin autoimmune syndrome](#). *Endocrinol Diabetes Metab Case Rep*. 2014; 2014:130086.

doi: 10.1530/EDM-13-0086. Epub 2014 Apr 1.

5. V. Marks and **G. Wark**. [Forensic aspects of insulin](#). Diabetes Research and Clinical Practice 2013; 101 (3): 248 – 254.
6. S. Kalathil, C Napier, S.J. Pattman, **G. Wark**, K. Abouglila and R.A. [James](#). [Insulin assays: Variable characteristics illustrated by a case of hypoglycaemia](#). Practical Diabetes 2013; 30(3): 118–120.
7. R. Kay, D.J. Halsall, A.K. Annamalai, N. Kandasamy, K. Taylor, S. Fenwick, A. Webb, **G. Wark**, S. Pleasance and M. Gurnell. [A novel mass spectrometry based method for determining insulin-like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly](#). Clin Endocrinol 2013; 78(3): 424-430.
8. S.J Redding, **G. Wark** and C. Livingstone. [Clinical Validation of ELISA Assays for Insulin-Like Growth Factor-II \(IGF-II\)](#). J Endocrinol Metab 2012; 2(2): 72-81.
9. A. Borai, C. Livingstone, M. Ghayour-Mobarhan, A. Abuosa, S. Shafi, S. Mehta, A. Heidari, A. Emadzadeh, **G. Wark** and G. Ferns. [Serum insulin-like growth factor binding protein-1 \(IGFBP-1\) phosphorylation status in subjects with and without ischaemic heart disease](#). Atherosclerosis 2010; 208 (2): 593-598.
10. D. Hill, K. Livingstone, J.E. Thomson, C. Perry and **G. Wark**. [IGF-II Secreting Solitary Fibrous Tumour of the liver presenting with hypoglycaemia](#). Scottish Medical Journal 2008; 53 (1): 60.
11. A. Pokrajac, **G. Wark**, A.R. Ellis, G.E. Wieringa and P.J. Trainer. [Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice](#). Clinical Endocrinology 2007; 67 (1): 65-70.
12. D.J. Halsall, M. Mangi, M. Soos, M.N. Fahie-Wilson, **G. Wark**, R. Mainwaring-Burton and S. O’Rahilly. [Hypoglycemia due to an insulin binding antibody in a patient with IgA- \$\kappa\$  myeloma](#). JCEM 2007; 92 (6): 2013-2016.
13. A.H. Heald, B. Bhattacharya, H. Cooper, A. Ullah, A. McCulloch, S. Smellie and **G. Wark**. [Most commercial insulin assays fail to detect recombinant insulin analogues](#). Ann Clin Biochem. 2006; 43 (4): 306-308.
14. J.M. Monaghan, I.M. Godber, N. Lawson, M. Kaur, **G. Wark**, D. Teale and D.J. Hosking. [Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy](#). Ann Clin Biochem 2004; 41 (3): 220-206.
15. J.D. Teale and **G. Wark**. [The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia](#). Clinical Endocrinology 2004; 60(4): 457-460.
16. A. Powell, **G. Wark**, C Mills and C. Livingstone. Assessment of the clinical potential of an immunoenzymometric assay for insulin-like growth factor binding protein-1. Chemical Pathology 2004; 1: 29-30.
17. G.A.A. Ferns, D. O’Dowd, **G. Wark** and N. Collins. [Molecular diagnostics in routine practice: quality issues and application to complex disease](#). Ann Clin Biochem 2003; 40(4):309-312.

18. J.D. Teale, **G. Wark** and V. Marks. [The biochemical investigation of cases of hypoglycaemia: an assessment of the clinical effectiveness of analytical services](#). *Journal of Clinical Pathology* 2002; 55 (7): 503-507.